Inventiva

Equities

IVA

FR0013233012

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:35:25 2024-04-25 am EDT			After market 03:12:19 pm
3.04 ^EUR	+0.66%		3.053	+0.43%

Apr. 22	Inventiva: UBS Group falls below 5% threshold	CF
Apr. 18	Transcript : Inventiva S.A. - Special Call

Inventiva announces participation at several investor conferences in November 2021

October 29, 2021 at 09:41 am EDT

Daix (France), Long Island City (New York, United States), November 29, 2021 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that the Company's leadership will participate in two upcoming conferences in November 2021.

Download PDF

Attachments

Original document
Permalink

Disclaimer

Inventiva SA published this content on 29 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 October 2021 13:40:28 UTC.

Latest news about Inventiva

Inventiva: UBS Group falls below 5% threshold	Apr. 22	CF
Transcript : Inventiva S.A. - Special Call	Apr. 17
Canaccord Genuity Adjusts Price Target on Inventiva to $20 From $12, Maintains Buy Rating	Apr. 08	MT
INVENTIVA : Canaccord Genuity raises target	Apr. 08	CF
Transcript : Inventiva S.A., 2023 Earnings Call, Mar 28, 2024	Mar. 28
Inventiva S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
ADRs End Flat, Ehang Holdings Ltd. Climbs 15.6%	Mar. 19	DJ
Transcript : Inventiva S.A. - Special Call	Mar. 19
Inventiva: positive results from phase 2 clinical trial	Mar. 19	CF
Inventiva S.A. Announces Positive Results from the Phase II, Legend, Proof-Of-Concept Study Combining Lanifibranor with Empagliflozin	Mar. 18	CI
Inventiva: NATiV3 study pause lifted	Mar. 08	CF
Inventiva Resumes Patient Recruitment for Lanifibranor Clinical Trial	Mar. 08	MT
Inventiva Announces Voluntary Pause on Screening and Randomization of Its NATiV3 clinical trial	Mar. 07	CI
ADRs Close Higher, Ambow Education Holding Ltd. Climbs 117.4%	Feb. 16	DJ
Inventiva Shares Plunge After Halting Recruitment for Clinical Trial NATiV3; Reports Preliminary Revenue	Feb. 16	MT
Stifel Cuts Price Target on Inventiva to $25 From $27, Maintains Buy Rating	Feb. 16	MT
Inventiva: share price falls, phase III recruitment suspended	Feb. 16	CF
Inventiva S.A. Provides Update on its Clinical Trial NATiV3	Feb. 15	CI
Inventiva: second tranche drawn from the EIB	Jan. 11	CF
Inventiva Draws Down EUR25 Million from Loan to Fund Lanifibranor Trial	Jan. 11	MT
HC Wainwright Adjusts Price Target on Inventiva to $24 From $36, Keeps Buy Rating	Dec. 21	MT
Inventiva: first randomization in China for NATiV3	Dec. 21	CF
Inventiva Says First Person Randomized in China in Phase 3 Trial of Lanifibranor for Nonalcoholic Steatohepatitis	Dec. 20	MT
Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development Program	Dec. 20	CI
Canaccord Genuity Initiates Inventiva at Buy Rating With $12 Price Target	23-10-27	MT

Chart Inventiva

Duration

Period

More charts

Company Profile

Inventiva is a biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology. The group is developing two drug candidates - lanifibranor and odiparcil - in non-alcoholic steatohepatitis (« NASH ») and mucopolysaccharidosis (« MPS ») respectively, as well as a portfolio of several programs in the preclinical stage. Lanifibranor, is currently in a pivotal Phase III clinical trial « NATiV3 » for the treatment of patients with MASH/NASH and Odiparcil is currently in Phase IIa for the treatment of type VI MPS. As part of Inventiva's decision to focus clinical efforts on the development of Lanifibranor, it suspended clinical efforts relating to Odiparcil and is reviewing available options with respect to its potential further development. Meanwhile, Inventiva is in the process of selecting an oncology drug candidate for the Hippo signaling pathway.

Sector

Biotechnology & Medical Research

Calendar

2024-05-15 - Gilbert Dupont MIDCAPS Forum

More about the company

Income Statement Evolution

More financial data

Ratings for Inventiva

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.02 EUR

Average target price

13.83 EUR

Spread / Average Target

+358.06%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
INVENTIVA	-25.76%	168M
VERTEX PHARMACEUTICALS INCORPORATED	-1.96%	104B
REGENERON PHARMACEUTICALS, INC.	+1.80%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.73%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-17.37%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+3.51%	13.98B
SAREPTA THERAPEUTICS, INC.	+33.27%	11.66B

Bio Therapeutic Drugs